Refined Diagnostics raised 2900000 EUR in growth capital. The financing was supplemented by 2600000 EUR in public funding from the European Union, the German federal government, and the state of North Rhine-Westphalia. The round was led by the Companisto Business Angel Netzwerk together with existing and new co-investors. The company plans to use the fresh capital for medical device approval, completion of ongoing clinical studies, CE marking as an in-vitro diagnostic, and building production and sales ahead of a planned clinical market entry in 2027.
About Refined Diagnostics
Refined Diagnostics is a MedTech startup developing an imaging diagnostic system based on Raman laser technology for cancer diagnostics. The system analyzes the molecular fingerprint of tissue and aims to distinguish healthy and diseased tissue within minutes, including during surgical procedures. The company also develops laser systems for research institutions worldwide for applications including Raman microscopy and quantum technology.
Münster, Germany
Read Company ProfileFrequently Asked Questions
What type of funding round did Refined Diagnostics raise?
Refined Diagnostics raised a unspecified round.
How much did Refined Diagnostics raise in its unspecified?
Refined Diagnostics raised $2,900,000 EUR in its unspecified.
When did Refined Diagnostics raise its unspecified?
Refined Diagnostics raised its unspecified on 2026-07-07.
Who invested in Refined Diagnostics's unspecified?
The investors in Refined Diagnostics's unspecified are: Companisto Business Angel Netzwerk, existing and new co-investors.
What type of investment was Refined Diagnostics's unspecified?
Refined Diagnostics's unspecified was a equity investment.
How will Refined Diagnostics use the funds from its unspecified?
Refined Diagnostics plans to use the funds for: medical device approval, completion of ongoing clinical studies, CE marking as an in-vitro diagnostic (IVD), build production, build sales.